Literature DB >> 20977845

[Application of Lund concept in treating brain edema after severe head injury].

Chang-Wen Liu1, Yong-Ke Zheng, Jun Lu, Wen-Hua Yu, Bo Wang, Wei Hu, Ke-Yi Zhu, Ying Zhu, Wei-Hang Hu, Jian-Rong Wang, Jian-Ping Ma.   

Abstract

OBJECTIVE: To explore if the new treatment with Lund concept could reduce the mortality of patients after severe brain injury.
METHODS: This study included 68 severe brain injury patients in whom Gloasgow coma score (GCS) was 3-8, and in 30 of them Lund concept was adopted, and the other 38 patients were taken care of by the conventional treatment in controlling intracranial pressure (ICP). Furthermore, in patients of the Lund group and control group ICP and cerebral perfusion pressure (CPP) were monitored continuously for 5 days.
RESULTS: The amount of mannitol (g) used was markedly smaller in Lund group than that in the control group (139.6±25.0 vs. 587.5±31.8, P<0.01). The 28-day mortality of Lund group was significantly lower than that in control group (30.0% vs. 57.9%, P<0.05). In Lund group, the incidence of ICP exceeding 25 mm Hg (1 mm Hg=0.133 kPa) or 35 mm Hg or lowering of CPP by 50 mm Hg observed in the non-survivors (n=9) was greater than that observed in the survivors [n=21, (45.0±23.2)% vs. (7.2±3.6)%, (40.2±18.6)% vs. (2.2±1.6)%, (35.9±12.9)% vs. (3.1±2.4)%, all P<0.05].
CONCLUSION: By adopting the Lund concept, it is possible to reduce postoperative mortality after severe head injury.

Entities:  

Mesh:

Year:  2010        PMID: 20977845

Source DB:  PubMed          Journal:  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue        ISSN: 1003-0603


  2 in total

Review 1.  Use of Hyperoncotic Human Albumin Solution in Severe Traumatic Brain Injury Revisited-A Narrative Review and Meta-Analysis.

Authors:  Christian J Wiedermann
Journal:  J Clin Med       Date:  2022-05-09       Impact factor: 4.964

Review 2.  Critical Evaluation of the Lund Concept for Treatment of Severe Traumatic Head Injury, 25 Years after Its Introduction.

Authors:  Per-Olof Grände
Journal:  Front Neurol       Date:  2017-07-04       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.